ABSTRACT

Conclusion:

IVTA injection resulted statistical significant increasement in the visual acuity in macular edema secondary to diabetes mellitus and CRVO. There was not any significant IOP change starting from the 1st month till the 6th month after the injection.

Results:

Mean visual acuity before and 1st, 3rd, 6th months after injections were 0.87± 0.58, 0.82±0.55, 0.73±0.49, 0.72±0.46 in diabetic macular edema group; 1.35±0.35, 1.22±0.45, 1.18±0.47, 1.17±0.49 in CRVO group; 1.12± 0.49, 0.94±0.54, 0.90±0.57, 0.85±0.61 in BRVO group; 1.25±0.45, 1.33±0.37, 1.20±0.53, 1.31±0.42 in ARMD group, respectively. The only statistical significant increasement in visual acuity was detected in the 3rd (*p:0.003, *p:0.044) and 6th month (*p:0.002, *p:0.046) in the diabetic macula edema and CRVO groups. The visual acuity alterations in other groups and IOP alterations in all groups did not show any significant difference from the baseline (p>0.05). In FFA at the 6 th month, in diabetic macular edema group and CRVO group macular edema markedly decreased in 15 eyes (%32) and 10 eyes (%59), minimally decreased in 25 eyes (%53) and 7 eyes (%41), respectively. In BRVO group in 7 eyes (%100) decreased minimally. In ARMD patients there was not any documented leakage.

Method:

We evaluated the best corrected visual acuity (LogMAR), fundus şuorescein angiography (FFA) and intraocular pressure (IOP) before and 1st, 3rd, 6th months after IVTA injection in 97 eyes of 87 patients consisted from diabetic macular edema (47 eyes), central retinal (CRV) (17) and branched retinal vein occlusion (BRVO) (7) and age-related macular degeneration (ARMD) (26) patients, retrospectively.

Purpose:

To evaluate the outcome of our 4 mg intravitreal triamcinolone acetonide (IVTA) injections.